Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Search for New Prostate Cancer Targets Yields a Profusion of Options

September 11th 2019

Despite the introduction of novel therapies over the past decade, advanced prostate cancer remains an incurable disease in need of new strategies to overcome drug resistance.

Dr. Kohli Discusses Ongoing Correlative Science in Prostate Cancer

September 11th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.

Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer

September 10th 2019

Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Henderson on Anticipated Developments With Radiotherapy in Prostate Cancer

September 10th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses anticipated developments with radiotherapy in prostate cancer.

Real-World Data With Sipuleucel-T Showcase Promising OS in mCRPC

September 5th 2019

Sipuleucel-T (Provenge) was associated with a median overall survival of 47.7 months in a subgroup of patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer.

Dr. Jain on Radioligand Therapy in Prostate Cancer

September 5th 2019

Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.

Dr. Kohli on Sequencing Concerns in Metastatic Hormone-Sensitive Prostate Cancer

September 4th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

Tracers Increase PET Imaging Sensitivity in Prostate Cancer

August 27th 2019

Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.

Research Initiative Comparing Proton Therapy With IMRT in Prostate Cancer

August 27th 2019

Randal Henderson, MD, MBA, discusses the data that led to the PCORI-funded trial, what the results could mean for the field, and interesting research on the horizon.

Armamentarium Continues to Evolve Across Metastatic Prostate Cancer

August 26th 2019

Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.

Dr. Henderson on Proton Therapy Versus IMRT in Prostate Cancer

August 22nd 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology and associate medical director at the University of Florida Health Proton Therapy Institute, discusses the potential benefits of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

FDA Grants Enzalutamide Priority Review for Metastatic Hormone-Sensitive Prostate Cancer

August 21st 2019

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.

Dr. Jain on the Indications for PET Imaging in Prostate Cancer

August 20th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Dr. Henderson on the Benefits of Proton Therapy in Prostate Cancer

August 16th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in prostate cancer.

Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy

August 15th 2019

Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib in combination with the hormone blocker abiraterone in men with metastatic castration-resistant prostate cancer who have received no prior cytotoxic chemotherapy or new hormonal agents.

Dr. Tan on Imaging Modalities in Prostate Cancer

August 15th 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.

Dr. Jain on Novel Imaging Technologies for Prostate Cancer

August 13th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses new imaging modalities to detect disease in patients with prostate cancer.

Nonmetastatic CRPC Paradigm Bursting With Influx of AR Inhibitors

August 12th 2019

Winston Tan, MD, discusses the influx of treatment options in nonmetastatic castration-resistant prostate cancer and the modalities that are being used in an effort to ensure their optimal use.

Vogelzang Highlights Decades of Innovation in Prostate Cancer

August 12th 2019

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses groundbreaking developments that have transformed the treatment of prostate cancer, as well as current issues in urology.

Where Sipuleucel-T Fits in the Treatment of mCRPC

August 9th 2019

Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.